China’s largest innovative domestic drug maker will only take global those products that play into its strengths, chairman Piaoyang Sun declares.

Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.

MoonLake of Switzerland is heading to the NASDAQ armed with $230m to take its tri-specific IL17A/IL-17F nanobody sonelokimab, acquired from Merck KGaA, into the highly competitive spaces of psoriatic arthritis, ankylosing spondylitis and hidradenitis suppurativa.

The company plans to file PT027, a new fixed-dose combination of albuterol and budesonide, in 2022 following two positive Phase III trials showing a benefit on lung function.